Shares of Prime Medicine, Inc. (PRME) have gained 18% over the past four weeks to close the last trading session at $6.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 133.6%.The average comprises 10 short-term price targets ranging from a low of $9 to a high of $21, with a standard deviation of $4.32. While the lowest estimate indicates an ...